Committed Investment: August, 2022
Status: Active Portfolio Company
Tundra Targeted Therapeutics is developing novel bispecific antibodies to treat cancer. The antibodies will bring a patient’s own T cells into contact with specific antigens on tumor cells. This schema will provide targeted cancer cell killing with fewer side effects than current approaches, and without the costs and risks of genetic engineering. Tundra was founded by cancer researchers and clinicians at the Medical College of Wisconsin, Children’s Wisconsin, and Froedtert Hospital.